	US 12,285,546 B2
	Animal fat-derived extracellular matrix, and preservation solution of animal fat-derived extracellular matrix
Yong-Woo Shin, Seongnam-si (KR); Seong-Rae No, Seongnam-si (KR); Min-Cheol Kook, Seongnam-si (KR); Kyu-Byung Kim, Gwangju-si (KR); Yoon-Hee Seol, Seongnam-si (KR); and Jee-Hoon Shin, Seongnam-si (KR)
Assigned to DOF INC., Daejeon (KR)
Appl. No. 17/594,602
Filed by DOF INC., Hwaseong-si (KR)
PCT Filed Nov. 21, 2019, PCT No. PCT/KR2019/016067 § 371(c)(1), (2) Date Oct. 22, 2021, PCT Pub. No. WO2021/040141, PCT Pub. Date Mar. 4, 2021.
Claims priority of application No. 10-2019-0105041 (KR), filed on Aug. 27, 2019.
Prior Publication US 2022/0202995 A1, Jun. 30, 2022
Int. Cl. A61L 27/54 (2006.01); A61L 27/36 (2006.01)

CPC A61L 27/54 (2013.01) [A61L 27/36 (2013.01)]

5 Claims

1. An animal fat-derived extracellular matrix with increased biosafety and biocompatibility, which has undergone decellularization and fat removal and includes growth factors,

wherein the decellularization and fat removal and the inclusion of growth factors are carried out through a solvent extraction process using supercritical fluid,

wherein the growth factor is selected from the group consisting of AR, bFGF, b-NGF, EGF, EGFR, FGF-6, FGF-7, GCSF, GDNF, GM-CSF, HB-EGF, HGF, IGFB P-1, IGFB P-2, IGFB P-3, IGFB P-4, IGFB P-6, IGF-I, IGF-ISR, IGF-II, M-CSF, M-CSFR, NT-3, NT-4, PDGFRa, PDGFRb, PDGF-AA, PDGF-AB, PDGF-BB, PIGF, SCF, SCFR, TGF-a, TGF-b, TGF-b2, TGF-b3, VEGF, VEGFR2, VEGFR3, VEGF-D, and any combination thereof, and

wherein the growth factor is comprised in an amount of 0.52 to 11.19 ng per 1 g of the extracellular matrix.

3. An animal fat-derived extracellular matrix preservation solution, wherein it comprises 0.1 to 5 parts by weight of an animal fat-derived extracellular matrix that has undergone decellularization and fat removal through a solvent extraction process using supercritical fluid and comprises certain growth factors; and 95 to 99.9 parts by weight of a dispersion, and is filtered.